...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Protagen to Apply UNIarray Platform for Biogen Idec

| Print |
Tuesday, 29 March 2011 09:30 (UTC + 2)

Protagen_logo

Dortmund, Germany, March 29, 2011 / b3c newswire / - Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis announced today that they will be using the UNIarray® Platform to help discover biomarkers in relapsing remitting multiple sclerosis for Biogen Idec, Inc. Under the terms of the agreement, Protagen will apply its UNIarray® technology platform and expertise in autoantibody research to support retrospective analysis of samples from a Biogen Idec clinical trial for the purpose of finding predictive and response biomarkers associated with multiple sclerosis (MS) therapy.

 

“There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic level markers,” said Dr. Peter Schulz-Knappe, CSO of Protagen AG. “Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression.”

 

“Pharmaceutical companies recognize more and more the importance of autoantibody signatures for drug development, and Protagen provides the right technology and unique expertise for collaborations in this area”, said Dr. Stefan Müllner, CEO.

 

Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer and neurodegenerative disorders. The systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs. UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.

 

 

About Protagen AG - www.protagen.de

Protagen AG is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.

 

 

Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel:   +49 (0) 231 9742 6300
Fax:  +49 (0) 231 9742 6301

E-Mail:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it  

 

Media Enquiries
Bettina Franz
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel:   +49 (0) 231 9742 6300
Fax:  +49 (0) 231 9742 6301

E-Mail:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it